The ongoing shortage of an epilepsy medication, Teva-clobazam, is causing concern among patients who fear experiencing seizures if they switch to an alternative, according to the Canadian Epilepsy Alliance. The shortage, which started in May and is expected to last until April next year, has patients scrambling to find doses at different pharmacies. While an alternative version, Apo-clobazam, is available, experts warn that not all patients can interchange the medications without risking breakthrough seizures.
Dr. Eduard Bercovici, a Toronto neurologist specializing in epilepsy, emphasized the devastating impact drug shortages can have on individuals relying on them to prevent seizures. The reason cited for the Teva-clobazam shortage is a disruption in the drug’s manufacturing process. Despite inquiries for more details, the manufacturer, Teva Canada, has not provided additional information.
Bercovici explained that both Teva-Clobazam and Apo-Clobazam are benzodiazepines that are essentially the same; however, some individuals with epilepsy are sensitive to changes between the two and may experience adverse effects, including a return of seizures. This sensitivity can occur with either medication, underscoring the challenges faced by patients during the shortage.
The report highlighted the case of 90-year-old Rev. John Dickinson from Kitchener, Ont., who requires the Teva version of the medication due to adverse reactions to the alternative. His daughter, Rebecca Roland, shared the struggles they have faced in locating doses since the shortage began in August. Despite efforts to secure the medication by contacting pharmacies across Ontario, the limited availability has raised concerns about the continuity of treatment.
The Canadian Epilepsy Alliance estimates that around 260,000 Canadians have epilepsy, emphasizing the widespread impact of the medication shortage. Laura Dickson, president of the alliance, emphasized the importance of not disrupting stable medication regimens during shortages, as it can have serious implications for individuals’ daily lives and safety.
As the shortage persists, patients like Dickinson and his family are left navigating the challenges of securing essential medication and facing the uncertainty of potential treatment changes. The alliance and healthcare providers continue to advocate for solutions to mitigate the impact of the shortage on epilepsy patients across the country.
Leave feedback about this